Skip to content

KLRS KLRS Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$37.8M+24.8%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$2.08M+17.9%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$3.17M+47.0%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$11.66M+6.5%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$5.49M-3.4%
Regenxbio logo
RegenxbioRGNX
$7.87M-0.9%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's operating lease liabilities (current)?
KLRS (KLRS) reported operating lease liabilities (current) of $317K in Q1 2026.
What is the long-term trend for KLRS's operating lease liabilities (current)?
Over 4 years (2021 to 2025), KLRS's operating lease liabilities (current) has grown at a -53.2% compound annual growth rate (CAGR), from $6.59M to $316K.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.